Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide....
All News
Article
Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.
Article
A multinational study of polyarteritis nodosa (PAN) through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
Article
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
Article
The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis. A subsequent analysis of these patients showed several candidate biomarkers that may correlate with baseline and treatment‐associated changes in arterial inflammation in patients with RA.
Dr. John Cush
Tweet
CD19 CAR T-Cell Therapy in Autoimmune Disease
The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.
https://t.co/D53xeBdgsu https://t.co/dkrJ2CiSTl
Dr. John Cush
Tweet
Fever of Unknown Origin: Not Always an Infection
Roel Sanchez Baez, MD presents his poster at RWCS 2024.
https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A
Dr. John Cush
Tweet
Excess Cardiovascular Risk in Gout
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR
Dr. John Cush
Tweet
Can Biomarkers Improve Cardiovascular Risk Assessments in RA?
The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis.
https://t.co/NTI57kTtAy https://t.co/idf4qTtKcw
Dr. John Cush
Tweet
It's a Sore Subject
Cindy Chiu, DO, presents her poster at RWCS 2024.
https://t.co/Bl7mAL4grR https://t.co/9rLglObu4V
Dr. John Cush
Tweet
Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open.
https://t.co/WApFsSzn1W https://t.co/jNv6MClCRk
Dr. John Cush
Tweet
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases.
https://t.co/FJtWtaxXeG https://t.co/olcRoFZrBY
Dr. John Cush
Tweet
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/YAjffGVATG https://t.co/5UWNpDNioT
Dr. John Cush
Tweet
As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9
Dr. John Cush
Tweet
In 2023, the FDA approved 956 generic drugs and issued 1,493 complete response letters; an improvement on 2022’s 914 approvals and 1,775 complete response letters. https://t.co/XnpQLbxJCr https://t.co/zzf63G4s2R
Dr. John Cush
Tweet
IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%). https://t.co/drFAtBG4ZU https://t.co/N8ixHS64HD
Dr. John Cush
Tweet
Mastery of knee arthrocentesis for internal medicine resident
Brian D. Jaros, MD, presents his poster at RWCS 2024.
https://t.co/xFoEGnj2QH https://t.co/DpW07jJTLf
Dr. John Cush
Tweet
EGPA: Benralizumab (BEN) or Mepolizumab (MEP)
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA.
https://t.co/1F8hBCOaFV https://t.co/smTSIY1HA3
Dr. John Cush
Tweet
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
https://t.co/sLgoCRAavP https://t.co/NibyFpPzmW
Dr. John Cush
Tweet
Neonatal Fc receptor mAb (lowers Igs) development:
2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis
2023 FDA approved rozanolixizumab (Rystiggo) for MG
2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG
INTERESTING? https://t.co/Ou9An9EvUK https://t.co/XDDELNAYYD
